GlassScriptPhysician profile
Janice W Chan
NPI 1306133350
$3,463.27
in general payments reported to CMS, 2019-2025
25 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2022: $38.16 · 2023: $56.59 · 2024: $1,603 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $783.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $437.78 | 2024-2025 | |
| Lilly USA, LLC | $419.89 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $300.95 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $299.06 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $166.86 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $136.87 | 2019-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $122.48 | 2024-2025 | Capvaxive, Gardasil 9, Verquvo |
| Pfizer INC. | $100.67 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.52 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $75.79 | 2024-2025 | Spravato, Xarelto |
| Csl Behring | $66.61 | 2025 | Haegarda |
| Astellas Pharma US INC | $64.64 | 2024-2025 | Veozah |
| Abbott Laboratories | $57.84 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $56.73 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.21 | 2024 | Nexletol |
| Abiomed | $38.84 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $36.99 | 2024-2025 | |
| Grifols USA, LLC | $35.78 | 2019 | |
| Amgen INC. | $29.43 | 2019-2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $26.50 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.61 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2019 | |
| Antares Pharma, INC. | $17.47 | 2024 | Xyosted |
| Sanofi-Aventis U.S. LLC | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.